Corporate Presentations Corporate Presentation Aug 05, 2021 Data & Congress Presentations A Phase 1/2 study of Intratumoral INT230-6 Alone (IT-01) or in Combination with Pembrolizumab [KEYNOTE-A10] in Adult Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors Refractory to Therapy Source Presented at ASCO 2021 Early Results of Intratumoral INT230-6 Alone or in Combination with Ipilimumab in Subjects with Advanced Sarcomas Source Presented at ASCO 2021 Publications Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models Co-delivery of PLGA Encapsulated Invariant NKT Cell Agonist with Antigenic Protein Induce Strong T Cell-Mediated Antitumor Immune Responses PLGA Nanoparticles Co-encapsulating NY-ESO-1Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses
A Phase 1/2 study of Intratumoral INT230-6 Alone (IT-01) or in Combination with Pembrolizumab [KEYNOTE-A10] in Adult Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors Refractory to Therapy Source Presented at ASCO 2021
Early Results of Intratumoral INT230-6 Alone or in Combination with Ipilimumab in Subjects with Advanced Sarcomas Source Presented at ASCO 2021
Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models
Co-delivery of PLGA Encapsulated Invariant NKT Cell Agonist with Antigenic Protein Induce Strong T Cell-Mediated Antitumor Immune Responses
PLGA Nanoparticles Co-encapsulating NY-ESO-1Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses
